Navigation Links
Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
Date:12/8/2008

DUBLIN and NEWCASTLE, England, December 8 /PRNewswire/ --

- Marketing Partner UCB Expects to Receive Completed Price and Reimbursement Approval for Tetrabenazine in H1 2009

- Exclusive Distribution Rights Granted in Finland (MediFront) and Taiwan (Giddi Pharma); Distribution Contracts Renewed in Australia and New Zealand

Cambridge Laboratories Limited ("Cambridge" or "the Company"), the privately-owned specialty pharmaceutical company, today announces that its flagship product Tetrabenazine, (known as NITOMAN(R) in Germany and other key European territories and XENAZINE(R) in the UK, US and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

The Company also announces that it has recently signed distribution agreements for Tetrabenazine in Finland and Taiwan, and renewed existing arrangements in Australia and New Zealand.

Tetrabenazine will be marketed as NITOMAN(R) in Spain by Cambridge's marketing partner UCB upon successful completion of all related procedures. It has been approved for the treatment of movement disorders associated with Huntington's disease, a condition for which there is major unmet medical need.

Cambridge has recently renegotiated its agreements with UCB in Spain and Portugal, giving UCB ten year exclusive marketing rights to Tetrabenazine in Spain. UCB, a global biopharmaceutical company, is focused on severe diseases in three therapeutic areas - inflammation, oncology and neurology. The renegotiated terms follow UCB's acquisition of Celltech, Cambridge's former partner in Spain and Portugal, and the more recent merger of UCB with Schwarz Pharma.

UCB is currently in the process of applying for price and reimbursement in Spain and expects to have this procedure completed in the first half of 2009.

Mark Evans, CEO of Cambridge, said: "The granting of a license for Tetrabenazine in Spain follows a series of launches in key global territories, most notably the US where the product was launched last month and completes the approval process in the major 5 EU territories. The continued worldwide rollout of Tetrabenazine, with new agreements signed in Finland and Taiwan is affirmation of Cambridge's commitment to providing Huntington's disease patients with this important treatment. We are particularly pleased to have partnered in Spain with UCB, one of Europe's leading neurology players."

A spokesperson from UCB said: "Our expertise within the CNS arena will allow us to maximize the value of this potential new therapy for patients, physicians and our shareholders."

Further details in connection with the new licensing deals in Finland and Taiwan and the renewal of existing arrangements in Australia and New Zealand are set out below:

    - In Finland, Cambridge announced that it has granted exclusive rights to
      MediFront to market and distribute Tetrabenazine. Medifront has been
      distributing Tetrabenazine on a named patient basis in Finland for five
      years and will have responsibility for obtaining a marketing
      authorisation in Finland.

    - Cambridge has signed a marketing and distribution agreement with Giddi
      Pharma of Taiwan. Under the terms of the agreement Giddi will have
      exclusive rights to market and distribute Tetrabenazine in that
      territory, and will also be responsible for obtaining a marketing
      authorisation.

    - Cambridge has renewed its distribution agreement with its Australian
      partner, Orphan Australia, for the exclusive marketing and distribution
      rights for Tetrabenazine.

    - In New Zealand, Cambridge has renewed its contract with AFT
      Pharmaceuticals, a privately owned company with a focus on the
      Pharmaceutical Rx/OTC market, giving them a further 5 year term with
      Tetrabenazine (marketed as XENAZINE(R)).

About Cambridge Laboratories (Ireland) Limited

Cambridge is a fast growing, dynamic and entrepreneurial pharmaceutical company with extensive product development and commercialisation expertise focused on innovative products to treat diseases of the central nervous system. Cambridge has an exciting portfolio of products, both on the market and in development, derived from its proprietary discovery efforts and a carefully constructed network of international partnerships for research, development, sourcing and global commercialisation. Utilising this unusual business model, Cambridge is dedicated to delivering significant value to patients, physicians and partners around the world.

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialisation of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing around 12 000 people in over 40 countries, UCB achieved revenue of 3.6 billion Euro in 2007. UCB is listed on Euronext Brussels (symbol: UCB).

    For further details:
    Cambridge Laboratories
    Mark Evans, CEO +44-191-296-9369
    David Wildy, CFO +353-1-631-9352
    Financial Dynamics
    Jonathan Birt, John Dineen, +44-20-7831-7193


'/>"/>
SOURCE Cambridge Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
2. IBT Laboratories Expands its Menu of Tests for Immune Deficiency
3. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
4. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
7. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
10. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
11. Romark Laboratories Raises $18 Million in Institutional Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... -- Research and Markets has announced the addition ... Future" report to their offering. ... This research service on the global pharmaceutical ... provides a snapshot of the key participants in the market. ... from 2016 to 2020. The market is expected to grow at ...
(Date:1/20/2017)... 2017 Wells Specialty Pharmacy announces the acquisitions and ... in Winter Park, Florida and Pharm-EZ ... Operations have been consolidated into the 3796 Howell Branch Road ... announce that Chad Tomlinson , former Vice President of ... immediately. Mr. Tomlinson is a Graduate of Florida State University ...
(Date:1/20/2017)... -- Avillion LLP, a co-developer and financier of late-stage ... MD MBA as Chief Medical Officer. Dr Weinberg will be based ... ... spent more than 17 years as a pharmaceutical and biotech executive ... Over the course of his career, he has interfaced with the ...
Breaking Medicine Technology:
(Date:1/21/2017)... CA (PRWEB) , ... January 21, 2017 , ... ... Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for its ... for alumni, family, friends, and community. “Coming Home 2017” will be held ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of its new medical office in Petaluma, located at 167 Lynch Creek Way. ... access to SRO sports medicine and rehabilitation services and on-site x-ray ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... Austin, Texas Periodontist Dr. Dan Holtzclaw in media for its creos™ line of ... surgeries performed by Dr. Holtzclaw in which he utilizes creos™ allo.gain™ bone graft ...
(Date:1/20/2017)... ... 2017 , ... A new partnership between Goodwill® and Roadie, Inc. aims to ... from clothes to couches to dressers and bicycles. Roadie — the national on-the-way delivery ... Goodwill donation center through February 28th. , “January is an exciting time when ...
(Date:1/20/2017)... ... 2017 , ... Source Vitál Apothecary, a skin and body care company dedicated ... company had a successful visit to the 2017 ECRM Diet, Vitamin & Sports Nutrition ... in the nutritional, sports and health industries a chance to meet in private sessions ...
Breaking Medicine News(10 mins):